Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$15.38 USD
-0.07 (-0.45%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $15.40 +0.02 (0.13%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth F Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Teva Pharmaceutical Industries Ltd. has a market cap of $17.72B, which represents its share price of $15.45 multiplied by its outstanding shares number of 1.15B. As a large-cap company, TEVA's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
TEVA 15.38 -0.07(-0.45%)
Will TEVA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TEVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TEVA
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
TEVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key Metrics
Countdown to Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street Forecasts for Key Metrics
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
Other News for TEVA
Teva management to meet with Truist
Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2025 Earnings Call Highlights: Strong Growth in ...
Teva Pharmaceuticals (TEVA) Reports Continued Growth in Q2 2025
Truist Hosts Influential Meeting on July 30-31 with Focus on TEVA